Effect of Etelcalcetide vs Cinacalcet on Serum Parathyroid Hormone in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism | Zendy

Geoffrey A. Block | Zendy; David A. Bushinsky | Zendy; Sunfa Cheng | Zendy; John Cunningham | Zendy; Bastian Dehmel | Zendy; Tilman B. Drüeke | Zendy; Markus Ketteler | Zendy; Reshma Kewalramani | Zendy; Kévin Martin | Zendy; Sharon M. Moe | Zendy; Uptal D. Patel | Zendy; Justin Silver | Zendy; Yan Sun | Zendy; Hao Wang | Zendy; Glenn M. Chertow | Zendy

Open Access

Effect of Etelcalcetide vs Cinacalcet on Serum Parathyroid Hormone in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism

Author(s) -

Geoffrey A. Block,

David A. Bushinsky,

Sunfa Cheng,

John Cunningham,

Bastian Dehmel,

Tilman B. Drüeke,

Markus Ketteler,

Reshma Kewalramani,

Kévin Martin,

Sharon M. Moe,

Uptal D. Patel,

Justin Silver,

Yan Sun,

Hao Wang,

Glenn M. Chertow

Publication year - 2017

Publication title -

jama

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 4.688

H-Index - 680

eISSN - 1538-3598

pISSN - 0098-7484

DOI - 10.1001/jama.2016.19468

Subject(s) - cinacalcet , medicine , calcimimetic , placebo , secondary hyperparathyroidism , parathyroid hormone , urology , hemodialysis , adverse effect , hyperparathyroidism , alternative medicine , pathology , calcium

Secondary hyperparathyroidism contributes to extraskeletal calcification and is associated with all-cause and cardiovascular mortality. Control is suboptimal in the majority of patients receiving hemodialysis. An intravenously (IV) administered calcimimetic could improve adherence and reduce adverse gastrointestinal effects.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research